As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from ...

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

Northeastern Chinese company 3SBio to receive $1.25B, in addition to $100M equity investment, $150M for exclusive rights in ...

3SBio is a leading biotech drugmaker in China. It is one of the earliest biologics innovators in the country, launching EPIAO in 1998 and TPIAO in 2005, which are market-leading innovative drugs.

3SBio Inc., (HKEX:1530) ("3SBio" or 'the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, ...

3SBio Inc. (HKG:1530) just released its latest full-year report and things are not looking great. 3SBio missed earnings this time around, with CN¥5.3b revenue coming in 4.1% below what the ...

SHANGHAI, Sept. 11, 2019 /PRNewswire/ -- According to Morgan Stanley Capital International's (MSCI) latest set of ESG ratings, 3SBio has been upgr ...

3SBIO and shareholder CITIC Private Equity are offering 606.1 million shares at an indicative price range of HK$8.30 to HK$9.10 each, putting the total deal at up to HK$5.51 billion, ...

3SBio is a leading biopharmaceutical company in China. It is one of the earliest biologics innovators in the country, launching EPIAO in 1998 and TPIAO in 2005. The current portfolio is older ...

View real-time 3SBio (1530) live share price and historical data, charts, technical analysis, financial reports and other HK:1530 stock data today.